Cerevel Therapeutics

About Cerevel Therapeutics

Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). With a portfolio of experimental neuroscience therapies, including clinical-stage and pre-clinical compounds, Cerevel targets a broad range of CNS disorders such as Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.